@article{38995895db2446a39c66fe9c0c1ef7b6,
title = "Recent developments and therapeutic strategies against hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six additional systemic agents either approved or awaiting approval for advanced stage HCC. While these agents have the potential to improve outcomes, a survival increase of 2-5 months remains poor and falls short of what has been achieved in many other solid tumor types. The roles of genomics, underlying cirrhosis, and optimal use of treatment strategies that include radiation, liver transplantation, and surgery remain unanswered. Here, we discuss new treatment opportunities, controversies, and future directions in managing HCC.",
author = "Mark Yarchoan and Parul Agarwal and Augusto Villanueva and Shuyun Rao and Dawson, {Laura A.} and Llovet, {Josep M.} and Finn, {Richard S.} and Groopman, {John D.} and El-Serag, {Hashem B.} and Monga, {Satdarshan P.} and Wang, {Xin Wei} and Michael Karin and Schwartz, {Robert E.} and Tanabe, {Kenneth K.} and Roberts, {Lewis R.} and Gunaratne, {Preethi H.} and Allan Tsung and Brown, {Kimberly A.} and Lawrence, {Theodore S.} and Riad Salem and Singal, {Amit G.} and Kim, {Amy K.} and Atoosa Rabiee and Linda Resar and Yujin Hoshida and He, {Aiwu Ruth} and Kalpana Ghoshal and Ryan, {Patrick B.} and Jaffee, {Elizabeth M.} and Chandan Guha and Lopa Mishra and {Norman Coleman}, C. and Ahmed, {Mansoor M.}",
note = "Publisher Copyright: {\textcopyright} 2019 American Association for Cancer Research.",
year = "2019",
month = sep,
day = "1",
doi = "10.1158/0008-5472.CAN-19-0803",
language = "English (US)",
volume = "79",
pages = "4326--4330",
journal = "Cancer research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "17",
}